Cargando…
Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells
Sorafenib is a multikinase inhibitor used as a first-line treatment for advanced hepatocellular carcinoma (HCC), but it has shown modest to low response rates. The characteristic tumour hypoxia of advanced HCC maybe a major factor underlying hypoxia-mediated treatment failure. Thus, it is urgent to...
Autores principales: | Zhou, Tian-yi, Zhuang, Lin-han, Hu, Yan, Zhou, Yu-lu, Lin, Wen-kai, Wang, Dan-dan, Wan, Zi-qian, Chang, Lin-lin, Chen, Ying, Ying, Mei-dan, Chen, Zi-bo, Ye, Song, Lou, Jian-shu, He, Qiao-jun, Zhu, Hong, Yang, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967870/ https://www.ncbi.nlm.nih.gov/pubmed/27476430 http://dx.doi.org/10.1038/srep30483 |
Ejemplares similares
-
Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells
por: Dai, Xiao-Yang, et al.
Publicado: (2016) -
CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling
por: Chen, Zibo, et al.
Publicado: (2022) -
YAP Inactivation by Soft Mechanotransduction Relieves MAFG for Tumor Cell Dedifferentiation
por: Lv, Jiadi, et al.
Publicado: (2023) -
DNMT3a-dermatopontin axis suppresses breast cancer malignancy via inactivating YAP
por: Ye, Danrong, et al.
Publicado: (2023) -
Hypoxia‐induced YAP activation and focal adhesion turnover to promote cell migration in mesenchymal TNBC cells
por: Nguyen, Thi My Hang, et al.
Publicado: (2023)